|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 261.00 EUR | +0.58% |
|
+3.69% | +9.39% |
| 05/06 | Glenmark Pharmaceuticals Launches Generic Seizure Drug in US | MT |
| 04/06 | UCB and Biogen Inc. Demonstrate Clinical Profile of Dapirolizumab Pegol in Systemic Lupus Erythematosus At EULAR 2026 | CI |
| Capitalization | 4.97TCr 5.74TCr 4.56TCr 4.29TCr 7.99TCr 5,46700Cr 8.11TCr 54TCr 21TCr 2,64400Cr 22TCr 21TCr 9,19500Cr | P/E ratio 2026 * |
28.1x | P/E ratio 2027 * | 21.5x |
|---|---|---|---|---|---|
| Enterprise value | 4.86TCr 5.61TCr 4.46TCr 4.19TCr 7.81TCr 5,34400Cr 7.93TCr 53TCr 21TCr 2,58400Cr 21TCr 21TCr 8,98700Cr | EV / Sales 2026 * |
5.7x | EV / Sales 2027 * | 4.84x |
| Free-Float |
61.59% | Yield 2026 * |
0.56% | Yield 2027 * | 0.58% |
Last Transcript: UCB
Trading UCB
| 1 day | +0.58% | ||
| 1 week | +3.69% | ||
| Current month | +3.69% | ||
| 1 month | +12.99% | ||
| 3 months | +1.20% | ||
| 6 months | +5.45% | ||
| Current year | +9.39% |
| 1 week | 244.2 |  | 263.9 |
| 1 month | 228.7 | | 263.9 |
| Current year | 223 | | 289.5 |
| 1 year | 153.65 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 59 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 15/01 | Fiscal year | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/01 | Buy | Director | 500 | 0.0003% | ||
| 15/01 | Fiscal year | Executive/Senior Manager | 3,000 | 0.0015% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.58% | +3.69% | +60.42% | +215.07% | 5.74TCr | |
| +1.07% | +3.36% | +31.54% | -15.30% | 6.47TCr | |
| -0.74% | +34.00% | +34.00% | +34.00% | 3.99TCr | |
| +5.75% | +1.35% | -59.70% | -68.49% | 3.36TCr | |
| -0.57% | -0.34% | +49.85% | -35.35% | 2.88TCr | |
| +1.13% | +5.83% | +52.26% | +64.15% | 2.05TCr | |
| -8.04% | +0.53% | +81.62% | -63.20% | 1.88TCr | |
| +0.26% | -8.10% | +5.95% | +107.31% | 1.7TCr | |
| +0.27% | +1.00% | +45.38% | +107.72% | 1.64TCr | |
| +0.42% | +2.04% | +76.34% | +363.08% | 1.32TCr | |
| Average | +0.01% | +0.57% | +37.77% | +70.90% | 3.1TCr | |
| Weighted average by Cap. | +0.44% | +1.26% | +34.66% | +57.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 851.55Cr 983.32Cr 781.35Cr 735.13Cr 1.37TCr 94TCr 1.39TCr 9.29TCr 3.61TCr 45TCr 3.69TCr 3.61TCr 1,57600Cr | 963.34Cr 1.11TCr 883.93Cr 831.63Cr 1.55TCr 1,06000Cr 1.57TCr 11TCr 4.09TCr 51TCr 4.18TCr 4.09TCr 1,78300Cr |
| Net income | 176.73Cr 204.07Cr 162.16Cr 152.56Cr 284.15Cr 19TCr 288.6Cr 1.93TCr 750.14Cr 9.4TCr 766.25Cr 749.57Cr 33TCr | 227.77Cr 263.01Cr 208.99Cr 196.63Cr 366.22Cr 25TCr 371.95Cr 2.48TCr 966.79Cr 12TCr 987.55Cr 966.06Cr 42TCr |
| Net Debt | -112.02Cr -129.35Cr -102.78Cr -97Cr -180.11Cr -12TCr -182.92Cr -1.22TCr -475.46Cr -5.96TCr -485.68Cr -475.11Cr -21TCr | -310.42Cr -358.45Cr -284.83Cr -267.98Cr -499.12Cr -34TCr -506.92Cr -3.39TCr -1.32TCr -17TCr -1.35TCr -1.32TCr -57TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | 261.00 € | +0.58% | 2,21,161 |
| 04/26/04 | 259.50 € | +3.02% | 2,34,719 |
| 03/26/03 | 251.90 € | +1.45% | 1,87,603 |
| 02/26/02 | 248.30 € | -2.32% | 2,56,470 |
| 01/26/01 | 254.20 € | +0.99% | 2,53,342 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition